Atlas Trials

Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia

Clinical trial NCT05338190 · RECRUITING

Trial details

NCT number
NCT05338190
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Primary Immune Thrombocytopenia (ITP)
Start date
2022-11-14
Primary completion
2026-11-14
Enrollment
132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.